Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurovance, a US-based neuroscience-focused company has completed enrollment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020), a new non-stimulant being developed to treat adults with attention deficit hyperactivity disorder (ADHD).
Subscribe to our email newsletter
The company said that data from its pilot phase IIa efficacy study in adult ADHD showed efficacy in a range similar to stimulants.
The new trial will assess the abuse liability potential for centanafadine among recreational stimulant users and results are expected to be reported during fall 2014.
Neurovance president and CEO Anthony McKinney said this is the second major advancement in the development of centanafadine for adult ADHD.
"First, centanafadine’s efficacy was demonstrated in a pilot study presented at the Society of Biological Psychiatry Annual Scientific Meeting in May," McKinney said.
"Now this substantial HAL study will test centanafadine’s abuse profile against two powerful stimulants and placebo.
"If this registration-level study confirms the preclinical data, we can be more confident that centanafadine has the potential for less restrictive scheduling than the stimulants currently used to treat ADHD."
The company intends to show that centanafadine SR, a norepinephrine- and dopamine-preferring triple reuptake inhibitor, has the right ratio for the right patient, without abuse liability.
The HAL study is a five-arm clinical trial designed to assess the abuse liability potential for centanafadine at two doses among qualified recreational stimulant users compared to Schedule II comparators d-amphetamine or lisdexamfetamine (Vyvanse) or placebo.